Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is a rare, progressive, and often fatal condition caused by the accumulation of misfolded transthyretin (TTR) proteins as amyloid deposits in the heart. This leads to a gradual decline in cardiac function, reduced mobility, and eventual heart failure. Given the debilitating nature of the condition, patients often face significant barriers to participating in traditional clinical trials, including limited mobility, geographic distance, and the need for frequent in-person visits
This global Phase 3, randomized, double-blinded study – sponsored by a multinational biopharmaceutical company – aimed to evaluate the safety and efficacy of an investigational drug designed to lower circulating TTR levels and reduce amyloid formation in the myocardium.
HTS: Centering Trial Delivery Around Patients
MRN’s Home Trial Support (HTS) played a central role in improving trial access for patients worldwide. By conducting study visits directly in participants’ homes, MRN removed barriers to participation, ensuring patients could continue in the trial regardless of where they lived or mobility. Visits were conducted at patients’ primary residences, secondary homes, or even temporary holiday locations, with care adjusted to their needs and lifestyle.
Click the button below to read the full case study